Citations

Clear

184 citation(s) found for "Brenner, J".

Recent advances in screening, diagnosis, prognosis and personalized treatment of sepsis
Jones, Natalie N. Whitfield, Clements, Casey, Rasania, Shailee, Brenner, Thorsten, Liesenfeld, Oliver , Clements, Casey M. , Rasania, Shailee , Brenner, Thorsten

Mayo Clinic

European Journal of Microbiology and Immunology | July 30, 2026 | Volume: 16 | Issue: 3 | Pages: 155-172

10.1556/1886.2026.00039 | PMID 42531012 Get It

Abstract Sepsis is a multi-system physiological syndrome defined as a dysregulated host response to infection. Despite recent advances clinicians continue to depend on clinically or physiologically defined syndromes as poor classifiers and therefore fail to accurately predict outcome or responses to treatment. Recent studies suggest that advances in screening, diagnosis, prognosis, and treatment of sepsis can be used to tailor immunomodulatory therapies. In the present narrative review, we critically analyze important academic literature published between January 2025 and June 2026 with a focus on epidemiology, screening, diagnosis, prognosis and personalized management. We believe that sepsis care will soon be defined by the convergence of rapid diagnostics, multi-omics profiling, and artificial intelligence, enabling a shift from generalized treatment approaches toward truly personalized, dynamic patient management. While the scientific and technological foundation for this transformation is emerging rapidly, clinical validation using innovative (adaptive) clinical trial design is required. Successful implementation within routine care will require multidisciplinary collaboration, robust infrastructure, clinician and patient engagement, and healthcare systems capable of integrating innovation into practice. The coming years may see a paradigm shift in sepsis management comparable to advances observed in personalized management of malignancies.
Clarifying risk-factor associations with quantitative breast tumor features: a pooled analysis of 24 studies
Adams, Daniel , Hurson, Amber N. , Ahearn, Thomas U, Andrulis, Irene L, Antoniou, Antonis C, Auvinen, Päivi, Bane, Anita, González, Amy Berrington de , Bodelon, Clara, Bolla, Manjeet K. , Borrero, Maria , Brenner, Hermann, Brock, Ian W., Camp, Nicola J. , Cessna, Melissa H., Chanock, Stephen J, Chenevix-Trench, G, Copson, ER, Fh, Couch, Devilee, P, Easton, Douglas F, Eccles, Diana, Figueroa, Jonine D, Glendon, Gord, Hamann, U, Hartman, Mikael, Heemskerk-Gerritsen, Bernadette A M, Hodge, James M, Holleczek, Bernd, Hollestelle, A M, Mj, Hooning, Investigators, kConFab, Amor, David, Andrews, Lesley , Antill, Y , Rl, Balleine, Beesley, Jonathan, Bennett, Ian, Bogwitz, Michael, Bodek, Simon, Botes, Leon, Brennan, Meagan, Brown, Melissa, Buckley, Michael, Caldon, Liz, Campbell, Ian, Chakrabarti, Anannya , Chauhan, Deepa, Chauhan, Manisha, Christian, Alice, Cohen, Paul, Colley, Alison, Cui, James, Courtney, Eliza, Cummings, Margaret, Delatycki, Martin, Dickson, Rebecca, Dixon, Joanne, Duijf, Pascal, Edwards, Stacey, Farshid, Gelareh , Fellows, AM, Fenton, Georgina, Field, Michael, Flanagan, James, Fong, Peter, Forrest, Laura, Fox, Stephen, French, Juliet , Friedlander, Michael, Gattas, Mike, George, Peter, Greening, Sian, Harris, Marion, Harraka, Philip, Hayward, Nick, Hoskins, Cass , Hunt, Clare, James, Paul, Jenkins, Mark, Kidd, Alexa, Koehler, Jessica, Kollias, J, Lakhani, Sunil, Lawrence, Mitchell, Lee, Jason , Li, Shuai, Lindeman, Geoff, Lippey, Jocelyn, Lipton, Lara, Loi, Sherene, Mann, Graham, Marsh, Deborah, McLachlan, Sue Anne, Reed, Amy McCart, Milne, Roger, Nightingale, Sophie , O’Connell, Shona, O’Sullivan, Sarah, Reilly, Robert O', Ortega, David Gallego, Pachter, Nick, Pang, Jia-Min, Pathak, Gargi, Patterson, Briony, Phillips, Kelly, Pieper, Ellen, Ramus, Susan, Rickard, Edwina, Ragunathan, Abi, Robinson, Bridget, Skandarajah, Anita, Salisbury, Elizabeth, Saunders, Christobel, Saunus, Jodi, Scott, Rodney, Scott, Clare, Sexton, Adrienne, Shaw, Joanne, Shelling, Andrew, Srinivasa, Shweta , Simpson, Peter, Mc, Southey, Spurdle, Amanda, Taylor, Jessica, Taylor, Renea, Thorne, Heather, Trainer, A H, Tucker, Kathy , Visvader, Jane, Walker, Logan, Williams, Rachael, Winship, I, Young, Mary Ann, Zaheed, Milita , Investigators, S On Behalf Of The Chlovis Study, Tan, Veronique Kiak Mien , Lim, Geok Hoon, Tan, Ern Yu , Tan, Su-Ming, Iau, Philip Tsau Choong , Jakubowska, A, Jones, Michael E. , Jones, Louise , Jones, Brandt, Jung, Audrey, Kaaks, Rudolf, Keeman, Renske , Lawrence, Scott, Li, J M, Lubiński, J, Mannermaa, Arto, Manoochehri, Mehdi, Martens, John W M, Mesker, Wilma E, Muhammad, Noor , Obi, Nadia, Olson, Janet E, Patel, Alpa V, Prajzendanc, Karolina , Ruddy, Kathryn J, Safizadeh, Fatemeh , Schöttker, Ben, Tengström, Maria , Le, Teras, Timmermans, M, Tollenaar, RA, Vachon, Celine M, Wang, Q, Yang, Xiaohong R, Zamora, M Pilar, Chang-Claude, Jenny, Schmidt, M K, Pharoah, Paul D P, Abubakar, Mustapha, Eccles, Diana , Ahearn, Thomas U. , Eccles, Diana , Jones, Michael E , Jones, J. Louise , Berrington de Gonzalez, Amy , Antoniou, Antonis C. , Bane, Anita, Behrens, Sabine , Białkowska, Katarzyna , Bodelón, Clara , Brenner, Hermann , Broeks, Annegien , Chanock, Stephen Jacob , Chenevix‐Trench, Georgia , Copson, Ellen , Couch, Fergus J, Cox, Angela , Cross, Simon S. , Devilee, Peter , Dunning, Alison M. , Easton, Douglas F. , Figueroa, Jonine D. , Glendon, Gord, González‐Neira, Anna , Hartikainen, Jaana M. , Hartman, Mikael , Heemskerk‐Gerritsen, Bernadette A. M. , Ho, Peh Joo , Hodge, James M. , Holleczek, Bernd , Hollestelle, Antoinette , Hooning, Maartje J. , Investigators, kConFab, Balleine, Rosemary L. , Bennett, Ian, Bogwitz, Michael R. , Bodek, Simon , Botes, Leon P., Buckley, Michael , Cohen, Paul A. , Crook, Ashley , Courtney, Eliza , Dawson, Sarah‐Jane , DeFazio, Anna , Delatycki, Martin B. , Duijf, Pascal H. G. , Fellows, Andrew, Fenton, Georgina L. , Flanagan, James M. , Forrest, Laura Elenor , Friedländer, Michael , Harraka, Philip A. , Kidd, Alexa, Kollias, James, Lakhani, Sunil R. , Lawrence, Mitchell, Lindeman, Geoffrey J. , Lippey, Jocelyn , Loi, Sherene , Reed, Amy E. McCart , Milne, Roger L , Gallego‐Ortega, David , Pathak, Gargi, Pearn, Amy , Robinson, Bridget A. , Skandarajah, Anita Rohini , Salisbury, Elizabeth, Saunders, Christobel , Saunus, Jodi M. , Savas, Peter Stephen , Sexton, Adrienne , Shelling, Andrew Neil , Simpson, Peter, Spurdle, Amanda B. , Visvader, Jane E. , Williams, Rachael, Tan, Bien‐Keem , Lim, Geok Hoon , Kaaks, Rudolf , Lawrence, Scott M. , Lissowska, Jolanta , Mannermaa, Arto , Manoochehri, Mehdi, Mesker, Wilma E. , Mulligan, Anna Marie , Obi, Nadia , Olson, Janet E. , Osório, Ana , Ottewell, Penelope Dawn , Patel, Alpa V , Pita, Guillermo , Rashid, Muhammad Usman , Ruddy, Kathryn J. , Schöttker, Ben , Seibold, Petra , Tapper, William , Teras, Lauren R , Timmermans, Mieke, Vachon, Celine M. , Wesseling, Jelle , Yadav, Siddhartha , Chang‐Claude, Jenny , Schmidt, Marjanka K. , Abubakar, Mustapha , García‐Closas, Montserrat

Mayo Clinic

JNCI: Journal of the National Cancer Institute | July 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag244 | PMID 42498670 Get It

Abstract Background Breast cancer is etiologically heterogeneous, but which risk factors differ in their associations across tumor subtypes remains unclear. We conducted a large, pooled analysis to evaluate independent, dose-response associations between breast cancer risk factors and quantitative tumor features. Methods Analyses of 15,731 invasive breast cancers from 24 studies evaluated associations (p-trend) between reproductive and hormonal factors, body mass index (BMI), alcohol, smoking, and family history in relation to quantitative immunohistochemistry measures on tissue microarrays (ER, PR, HER2, KI67, TP53) and tumor grade. Analyses in a subset of 10 population-based studies estimated subtype-specific odds ratios (ORs) comparing cases to controls. A Bayesian False Discovery Probability (BFDP) <0.2 was used to identify associations with strong statistical evidence. Results Nulliparity and later age at menopause were associated with higher ER-positivity (p-trend=0.021 and 0.001, respectively), with corresponding OR[ER+] (95% CI) = 1.49 (1.16-1.90) for nulliparous vs. parous and 1.07 (1.03-1.11) per 5 years. Current combined menopausal hormone therapy (MHT) use was associated with lower grade (p-trend<0.001), with OR [grade1] = 3.37 (2.69-4.21) for current vs. never users. Higher BMI was associated with lower ER-positivity and higher grade in premenopausal women (p-trend<0.001 and <0.001), with OR[ER+] = 0.80 (0.74-0.87) and OR[grade1] = 0.75 (0.63-0.88) per 5 units, and with higher PR-positivity and higher grade in postmenopausal women (p-trend<0.001 and <0.001), with OR[PR+] = 1.08 (1.03-1.14) and OR[grade 3] = 1.10 (1.04-1.17) per 5 units. Conclusion This pooled analysis of 15,731 cases showed that nulliparity, age at menopause, MHT, and BMI have independent, dose-response associations with ER, PR, and grade, clarifying patterns of etiologic heterogeneity. Associations with HER2, KI67 and TP53, or other risk factors did not meet our threshold for strong evidence.
PRANA: A Deep Learning Method for Adapting Polygenic Risk Scores to Diverse Ethnic Groups
Levi, Hagai, Wang, Qin, Bolla, Manjeet K. , Dennis, Joe, Andrulis, Irene L., Antonenkova, Natalia, Au, Chun Hang, Freeman, Laura E. Beane, Bermisheva, Marina, Bodelon, Clara, Bojesen, Stig E., Brenner, Hermann, Brock, Ian W., Brüning, Thomas, Byers, Helen, Camp, Nicola J., Castelao, Jose E., Choi, Ji-Yeob, Chung, Wendy K., Collaborators, NBCS, Colonna, Sarah, Couch, Fergus J., Daly, Mary B., Devilee, Peter, Dörk, Thilo, Eliassen, A. Heather, Eriksson, Mikael, Evans, D. Gareth, Fasching, Peter A., Faw, Kierstin, García-Closas, Montserrat, Haiman, Christopher A., Hamann, Ute, Hartman, Mikael, Hooning, Maartje J., Hoppe, Reiner , Howell, Sacha J., Investigators, ABCTB, Investigators, SGBCC, Ito, Hidemi, Iwasaki, Motoki, Jakubowska, Anna, Jernström, Helena, Joseph, Vijai, Kaaks, Rudolf, Kang, Daehee, Khusnutdinova, Elza K., Kiprijanovska, Sanja , Koutros, Stella, Kristensen, Vessela N., Kurian, Allison W., Kwong, Ava, Lambrechts, Diether, Larson, Nicole L. , Marchand, Loic Le, Li, Shuai, Li, Jingmei, Lophatananon, Artitaya, Mannermaa, Arto, Matsuo, Keitaro, Maxwell, Whitney, Muir, Kenneth, Nevelsteen, Ines, Obi, Nadia, O’Brien, Katie M., Ofit, Kenneth, Ottewell, Penelope D., Patel, Alpa V., Plaseska-Karanfilska, Dijana, Prajzendanc, Karolina , Ramachandran, Dhanya, Rashid, Muhammad U., Saloustros, Emmanouil, Sandler, Dale P., Schöttker, Ben, Simard, Jacques, Southey, Melissa C., Stone, Jennifer, Teras, Lauren R., Truong, Thérèse, Weinberg, Clarice R., Yamaji, Taiki , Zheng, Wei, Easton, Douglas F., Elkon, Ran , Lambrechts, Diether , Lambrechts, Diether , Kurian, Allison W. , Li, Shuai , Lambrechts, Diether , Lambrechts, Diether , Kurian, Allison W , Li, Shuai , Levi, Hagai , Au, Chun , Augustinsson, Annelie , Freeman, Laura E. Beane , Behrens, Sabine , Bermisheva, Marina , Bodelón, Clara , Bogdanova, Natalia , Brenner, Hermann , Brock, Ian W., Brüning, Thomas , Byers, Helen, Camp, Nicola J. , Castelao, Jose E. , Choi, Ji-Yeob , Chung, Wendy K. , Colonna, Sarah V. , Couch, Fergus J. , Czene, Kamila , Daly, Mary B., Devilee, Peter , Dörk, Thilo, Evans, D. Gareth , Fasching, Peter A., Faw, Kierstin, Gago-Domínguez, Manuela , García‐Closas, Montserrat , Haiman, Christopher A. , Hartman, Mikael , Ho, Vikki , Ho, Peh Joo , Hooning, Maartje J. , Investigators, S On Behalf Of The Chlovis Study, Iwasaki, Motoki , Jakubowska, Anna, Jernström, Helena , Joseph, Vijai, Kaaks, Rudolf , Хуснутдинова, Э. К. , Koutros, Stella , Kristensen, Vessela N., Kwong, Ava , Marchand, Loı̈c Le , Li, Jingmei, Lophatananon, Artitaya , Mannermaa, Arto , Nevelsteen, Ines , Obi, Nadia , O’Brien, Katie M. , Ottewell, Penelope Dawn , Peterlongo, Paolo , Plaseska‐Karanfilska, Dijana , Radice, Paolo , Ramachandran, Dhanya , Romero, Atocha , Saloustros, Emmanouil , Sandler, Dale P. , Schöttker, Ben , Simard, Jacques , Southey, Melissa C. , Sugier, Pierre‐Emmanuel , Taylor, Jack A. , Teras, Lauren R. , Truong, Thérèse , Weinberg, Clarice R. , Yadav, Siddhartha , Dunning, Alison M. , Mavaddat, Nasim , Easton, Douglas F. , Michailidou, Kyriaki , Shamir, Ron

Mayo Clinic

No container title available | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.12.26357860 | PMID 42523604 Get It

Abstract Polygenic risk scores (PRSs), which quantify inherited susceptibility to complex traits and diseases, have emerged as valuable tools for risk stratification and precision medicine. Despite their promise, PRS developed on European cohorts often demonstrate substantially reduced predictive accuracy in non-European populations, due to differences in genetic architecture. The disproportionate representation of European ancestry cohorts in genome-wide association studies (GWAS) leads to inequitable deployment of PRS technologies across diverse populations. Here, we introduce PRANA (Polygenic Risk Adaptation via Neural-network Architecture), a deep learning framework that adapts an existing PRS developed on one population to other ancestries. Unlike methods that require large-scale GWAS in the target population, PRANA leverages pre-trained PRS models derived from European cohorts and adapts them using modestly sized cohorts from the target population. We evaluated PRANA on seven complex traits in South Asian, East Asian and Ashkenazi Jewish populations, as well as in selected smaller East Asian subpopulations where the scarcity of training data poses a particular challenge. PRANA mostly improved predictive performance of the baseline PRS models by 5%-20% in terms of effect size (β) and Nagelkerke’s R², and, in most cases, outperformed existing cross-ancestry multi-PRS approaches. These results highlight PRANA as a scalable and practical strategy to reduce disparities in genomic risk prediction and advance the equitable application of PRS in diverse populations.
Dispelling myths and misconceptions of constipation with a focus on stimulant laxatives
Lacy, Brian E. , Brenner, Darren M, Serra, Jordi , Pohl, Daniel, Andresen, Viola, Aran, Alèxia, Lacy, Brian , Lacy, Brian E. , Brenner, Darren M. , Pohl, Daniel , Andresen, Viola, Aran, Alexia

Mayo Clinic

Frontline Gastroenterology | June 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: flgastro-2025-103547

10.1136/flgastro-2025-103547 Get It

Myths and misconceptions about the evaluation and treatment of constipation persist. Many widely prevalent misconceptions about laxatives, specifically stimulant laxatives, interfere with the effective management of constipation. Although some of these myths and misconceptions have been dispelled in recent years, there is additional room for improving the awareness and understanding of the pathophysiology of constipation, the mechanisms of action and the efficacy and safety of available therapies. An evolution in our understanding of pathophysiology and the availability of new treatments requires that primary care practitioners be better positioned to treat this common disorder that reduces patients’ quality of life and negatively impacts the healthcare system. This review defines constipation and elucidates various factors that contribute to its aetiology, including lifestyle, dietary habits, medications and underlying medical conditions. This review addresses and refutes common myths and misconceptions about constipation, such as the belief that regular bowel movements must occur daily or the use of laxatives leads to dependence. This review also highlights the importance of distinguishing between normal and abnormal bowel habits and emphasises the need for individualised management approaches to address constipation effectively. Finally, the review discusses different classes of laxatives, dispelling misconceptions about their safety, efficacy and potential for misuse, with a specific focus on stimulant laxatives. In summary, this review enhances awareness and knowledge of this prevalent disorder, provides evidence-based insights into common myths and misconceptions surrounding constipation and promotes more informed decision-making regarding constipation and the use of laxatives.
Early Recognition of Treatment‐Responsive Rapidly Progressive Dementia: The Modified STAM3 m P Score
Steenhoven, Robin W. van , Satyadev, Nihal , Bastiaansen, A. E. M., Piura, Y. D., Kerstens, J., Crijnen, Yvette S. , Brenner, Juliëtte , Brand, T., Bienfait, T. M., Veenbergen, S., Vries, J. M. de, Jong, F A de , Dopper, E.G.P., Smitt, P.A.E. Sillevis, Seelaar, H., Titulaer, M. J., Titulaer, Maarten J. , Bastiaansen, Anna E.M. , van Steenhoven, Robin W , Satyadev, N , Crijnen, Y S , Brenner, J , Day, Gregory S , Titulaer, Maarten J , Piura, Yoav , Kerstens, Jeroen , Bienfait, Tessa M., Veenbergen, Sharon , Dopper, Elise G.P. , Seelaar, Harro , Day, Gregory S.

Mayo Clinic

Annals of Clinical and Translational Neurology | May 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/acn3.70434 | PMID 42203753 Get It

ABSTRACT Early identification of patients with treatment‐responsive rapidly progressive dementia (RPD) is important as early treatment improves outcomes. The STAM 3 P score identifies treatment‐responsive RPD using “high risk” presenting features. We optimized performance by adding a time component (i.e., dementia within 3 months) and validated the modified “STAM3 m P score” in two independent cohorts ( n = 302). A STAM3 m P score ≥ 1 identified 96% of patients with treatment‐responsive RPD; ≥ 3 features were highly specific (98%). These data suggest that ≥ 1 STAM3 m P features effectively identifies treatment‐responsive RPD and may be used to prioritize investigations, whereas ≥ 3 STAM3 m P features are highly specific and may inform early treatment decisions.
Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-
Bansal, Ajay, Stoffel, Elena M., Lim, Ramona , Burke, Carol, Hall, Michael J., Singh, Aparajita , Boardman, Lisa A., Samadder, Niloy Jewel, Ballestar, Veroushka, Muller, Charles, Scott, Aaron J. , Xu, Yanfei , Eickhoff, Jens, Meredith, Hyun, Aquila, Lanni , Szabó, Éva , Della’Zanna, Gary , Bengtson, Lisa, Schlom, Jeffrey, Donahue, Renee N., Horn, Lucas A., Palena, Claudia, Gulley, James L., Samaddar, Sohini, Moore, Dennis F., Sharma, Parth, Madan, Rashna , Hurley, Karen, Soon‐Shiong, Patrick , Gabitzsch, Elizabeth, Sender, Lennie, Brenner, Dean, Schuetze, Scott, Djuric, Zora, Barroilhet, L. E., Thompson, Patricia, Bauman, Julie, Khan, Seema, Vilar, Eduardo, Szabo, Eva , Stoffel, Elena M. , Stanich, Peter P. , Patel, Swati , Burke, Carol A. , Hall, Michael J. , Muller, Charles , Benante, Kelly A. , Eickhoff, Jens C. , Zaborek, Jen , Umar, Asad , Richmond, Ellen S. , Schlom, Jeffrey , Donahue, Renee Nicole , Toney, Nicole J. , Palena, Claudia , Gulley, James L , Moore, Dennis F., Djurić, Zora , Barroilhet, Lisa , Vilar, Eduardo

Mayo Clinic

Frontiers in Immunology | May 19, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2026.1809281 | PMID 42238576 Get It

Introduction Lynch syndrome (LS) is a hereditary cancer syndrome that increases risk for colorectal and other cancers. We hypothesize that vaccines against tumor-associated antigens CEA, MUC1, and brachyury, simultaneously delivered in an adenovirus serotype-5 vector (Tri-Ad5) combined with the immune-enhancing IL-15 receptor superagonist nogapendekin-alfa-inbakicept (NAI) will reduce the incidence of colorectal neoplasms in LS carriers. Methods In this ongoing phase IIB double-blind placebo-controlled trial, two open-label safety phases (SPs) assessed safety of Tri-Ad5 alone (SP1, n=10) and with added NAI (SP2, n=10). A randomized controlled trial (RCT) follows the SPs. After baseline colonoscopy, vaccine dosing occurs at weeks 0, 4 and 8; Tri-Ad5 alone in SP1 and Tri-Ad5 plus NAI in SP2, with identical boosters at Week 52. The RCT phase participants (n=138) were randomized to receive Tri-Ad5 plus NAI or placebo. All participants complete colonoscopy at Weeks 52 and 104 for assessment of the primary endpoint: cumulative colorectal neoplasm incidence. Secondary endpoints include safety, tolerability, and immunogenicity. Results All 20 SP participants (median age 57.5 (range 42–75), 70% female, 15% minority) received all prime and booster series. SP1 participants reported 139 adverse events (AEs) and SP2 participants reported 178. AEs were predominantly grade 1; no treatment-related serious adverse events (SAEs) occurred. The most common treatment-related AEs were reactogenic events including grade 3 rash (without skin necrosis or breakdown) at NAI injection site (100% of SP2 participants). The RCT phase (n=138) recently completed accrual. Discussion In LS carriers without active cancer, the combination of Tri-Ad5 + NAI was well-tolerated; the RCT phase is ongoing. Clinical Trial Registration https://clinicaltrials.gov/study/ , identifier NCT05419011.
Tumor mutational and microbial profiles of early-onset and later-onset colorectal cancers according to detailed tumor location: an international pooled analysis
Ugai, Tomotaka, Ugai, Satoko , Qu, Conghui, Toland, Amanda E., French, Amy J. , Gsur, Andrea , Chan, Andrew T., Guelpen, Bethany van, Lynch, Brigid, Um, Caroline Y., Newton, Christina, Thomas, Claire E., Buchanan, Daniel D., Drew, David, Goode, Ellen L., Aglago, Elom K., Brenner, Hermann, Figueiredo, Jane C., Huyghe, Jeroen R., Nowak, Jonathan A., Doheny, Kimberly F., Hsu, Li, Boardman, Lisa, Gunter, Marc J., Giannakis, Marios, Jenkins, Mark A., Obon-Santacana, Mereia, Hoffmeister, Michael, Song, Mingyang, Murphy, Neil, Campbell, Peter T., He, Qianchuan, Trinh, Quang M., Pai, Rish K. , Steinfelder, Robert S. , Berndt, Sonja I., Gruber, Stephen B., Gallinger, Steven, Zaidi, Syed H., Hudson, Thomas J., Moreno, Victor, Sun, Wei, Huang, Wen-Yi, Lin, Yi, Cao, Yin, Peters, Ulrike, Hullar, Meredith, Phipps, Amanda I., Ugai, Tomotaka , Chen, Yu , Qu, Conghui , Chan, Andrew T , Um, Caroline Y. , Thomas, Claire E. , Buchanan, Daniel D. , Drew, David A. , Aglago, Elom K. , Brenner, Hermann , Figueiredo, Jane C. , Huyghe, Jeroen R. , Nowak, Jonathan A. , Doheny, Kimberly F. , Gunter, Marc J. , Giannakis, Marios , Jenkins, Mark A. , Obón‐Santacana, Mireia , Hoffmeister, Michael , Murphy, Neil , Georgeson, Peter , Campbell, Peter T., Trinh, Quang M. , Berndt, Sonja I. , Brezina, Stefanie , Gruber, Stephen B. , Gallinger, Steven , Zaidi, Syed H., Harrison, Tabitha A. , Hudson, Thomas J , Moreno, Victor , Sun, Wei, Huang, Wen‐Yi , Wang, Xiaoliang , Lin, Yi, Peters, Ulrike , Hullar, Meredith A.J. , Phipps, Amanda I. , Ogino, Shuji

Mayo Clinic

International Journal of Surgery | May 6, 2026 | Volume: 112 | Issue: 5 | Pages: 11070-11085

10.1097/js9.0000000000003877 Get It

Background: Considering the pathophysiological importance of the intestine-passing microbiota, we hypothesized that the mutational and microbial profiles of colorectal cancer might gradually change along detailed anatomical locations and that these trends might differ by the age of diagnosis and the microsatellite instability (MSI) status. Methods: We assessed somatic mutations and selected bacterial species in colorectal carcinomas along the cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum, utilizing targeted sequencing data ( N = 5685) from the Genetics and Epidemiology of Colorectal Cancer Consortium and tissue microbial data ( N = 1389) from the Health Professionals Follow-up Study and Nurses’ Health Study. Results: There were decreasing trends from the cecum to rectum in the prevalence of gene mutations in the IGF/PI3K, receptor tyrosine kinase (RTK)/RAS, TGFB, and WNT signaling pathways (all P trend < 0.0001), as well as high levels of Bacteroides fragilis ( P trend < 0.0001) and high levels of Fusobacterium nucleatum ( P trend = 0.0029) (but not enterotoxigenic Bacteroides fragilis or pks+ Escherichia coli ). Conversely, TP53 pathway mutations showed an increasing cecum-to-rectum trend ( P trend < 0.0001). Similar to later-onset cases diagnosed at ages 50 years and older, in early-onset cases diagnosed under the age of 50 years, we found generally decreasing cecum-to-rectum trends of IGF/PI3K, RTK/RAS, TGFB, and WNT pathway mutations and an increasing cecum-to-rectum trend in TP53 pathway mutations. By contrast, the cecum-to-rectum prevalence-changing trends in IGF/PI3K, RTK/RAS, TGFB, and TP53 pathway mutations were present in non–MSI-high tumors but not in MSI-high tumors (all P interaction < 0.0052). Conclusion: Non–MSI-high colorectal cancers exhibited decreasing cecum-to-rectum trends of IGF/PI3K, RTK/RAS, and TGFB pathway mutations (and an increasing trend of TP53 pathway mutations), in contrast to MSI-high tumors that demonstrated no such trends. Our study highlights the importance of detailed colorectal subsite information combined with tumor molecular and microbial characteristics in colorectal cancer research.
Correction to: Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis
Lembo, Anthony J, Chey, W D, Harris, Lucinda A. , Frazier, Rosita, Brenner, Darren M., Chang, Lin, Lacy, Brian E., Edelstein, Susan, Yang, Yang, Zhao, Suling , Rosenbaum, David P. , Lembo, Anthony , Chey, William D. , Frazier, Rosita , Brenner, Darren M. , Chang, Lin , Lacy, Brian E. , Edelstein, Susan , Yang, Yang

Mayo Clinic

American Journal of Gastroenterology | May 4, 2026 | Volume: 121 | Issue: 7 | Pages: 1787-1787

10.14309/ajg.0000000000004025 | PMID 42080433 Get It

Moderate-dose doxorubicin does not affect right ventricular size or function parameters in lymphoma patients—a single-center study
Muslera, Eduardo Brenner, Ardila, María F Gomez, Garcia, Eduardo Tellez, Cerhan, James R, Villarraga, Hector R, Brenner-Muslera, Eduardo, Gomez-Ardila, Maria F, Tellez-Garcia, Eduardo, Gomez-Ardila, M F, Garcia, Eduardo Tellez, Cerhan, James R. , Villarraga, Hector R.

Mayo Clinic

European Heart Journal Open | February 21, 2026 | Volume: 6 | Issue: 2 | Pages: No page available

10.1093/ehjopen/oeag039 | PMID 42004910 Get It

Abstract Aims We sought to determine whether doxorubicin affected echocardiographic parameters of right ventricular (RV) size and function when compared with guideline defined values in patients with lymphoma. Methods and results We enrolled 356 patients with lymphoma from 2013 to 2020. Patients received a mean (SD) of 5.12 (1.48) chemotherapy cycles and a cumulative, body surface area–adjusted doxorubicin dosage of 243.6 (79.6) mg/m2. Echocardiographic assessments occurred at 3 time points: T0, baseline; T1, 3 to 6 months after starting doxorubicin (mean [SD], 5.1 [1.2] months); and T2, 6 to 18 months (mean [SD], 12.98 [2.6] months) after treatment. End-diastolic area remained unchanged (P = 0.12). End-systolic area increased from 10.55 cm2 at T0 to 11.41 cm2 at T1 and 11.32 cm2 at T2 (P &lt; 0.001). Fractional area change decreased from 46.67% at T0 to 44.35% at T1 and 44.40% at T2 (P = 0.003). Tricuspid annular plane systolic excursion decreased from 23.17 (4.14) mm to 22.39 (4.10) mm at T1, and 22.13 (3.88) mm at T2 (P = 0.006). S′ declined from 0.14 m/s at T0 to 0.13 m/s at T1 and T2 (P &lt; 0.001). Tricuspid regurgitant velocity (P = 0.58) and RV systolic pressure (P = 0.75) showed nonsignificant changes. RV free wall strain worsened from −26.29% at T0 to −25.37% at T2 (P = 0.001). All parameters remained within guideline defined values (P &lt; 0.001). No significant differences were noted across dosage groups: &lt;200, 200–300, and &gt;300 mg/m2. Conclusion Echocardiography derived parameters of right ventricular size and function remained within normal guideline-defined values throughout a follow-up of up to 12.98 ± 2.6 months.